Abstract Number: PB1127
Meeting: ISTH 2021 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: Polycythemia vera (PV) is a clonal disease that belongs to the group of myeloproliferative neoplasms. PV is characterized by thrombotic complications. Currently there is not general diagnostic laboratory method for the development of thrombosis. Activation of endothelium that can lead to endothelial dysfunction is one of the factors that contribute to the progress of thrombosis. Prevention of thrombotic complications is a major issue in the management of these patients.
Aims: Aim to compare the effect of cytoreductive and / or antiplatelet therapy on endothelium activation in patients with PV.
Methods: 38 patients were examined. 18 people were treated with acetylsalicylic acid in prophylactic doses (group 1) and 20 patients were on cytoreductive therapy in combination with antiplatelet agents (group 2). The control group consisted of 43 healthy individuals. Ristocetin cofactor activity and von Willebrand factor level (vWF R:Co and Ag vWF respectively) were determined. Microsoft office Excel and STATISTICA 12.0 was used. The results are given as median (Me) with 50% confidence intervals (CI). Mann-Whitney test was used to compare the studied groups. P<0.05 was considered statistically significant.
Results: The data are shown in the table. Patients on cytoreductive and antiplatelet therapy had a significant increasing of vWF R:Co and Ag vWF. Endothelial activation was more pronounced in the second group that is the sign of endothelial dysfunction in that patients and it is a potential risk factor of thrombotic complications.
| Parameters | Group 1 (n=18) | Group 2 (n=20) | Healthy controls (n=43) |
| vWF R:Co, % | 80.00 74.00-110.00 |
138.00*, ** 107.25-167.30 |
97.00 84.00-110.00 |
| Ag vWF, % | 118.70 91.90-143.30 |
143.75* 125.15-160.20 |
107.00 89.25-134.75 |
| *-p<0.05 compare to controls | |||
| **-p<0.05 differences between Group 1 and Group 2 | |||
Table 1
Conclusions: Patients with PV on cytoreductive and antiplatelet therapy have a higher damage to the vascular wall than that in patients on acetylsalicylic acid only. Endothelial dysfunction due to its activation is a generally recognized risk factor for thrombotic complications.
To cite this abstract in AMA style:
Silina N, Korsakova N, Golovina O, Fominykh M, Efremova E, Voloshin S, Papayan L. Endothelial Dysfunction in Patients with Polycythemia Vera on Cytoreductive and / or Antiplatelet Therapy [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/endothelial-dysfunction-in-patients-with-polycythemia-vera-on-cytoreductive-and-or-antiplatelet-therapy/. Accessed June 25, 2022.« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/endothelial-dysfunction-in-patients-with-polycythemia-vera-on-cytoreductive-and-or-antiplatelet-therapy/